We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
WuXi Biologics and Bioasis Technologies, Inc. have entered an initial strategic collaboration for the development and manufacture of xB3-001, Bioasis' lead biologic candidate to treat brain cancer.